Facebook Twitter LinkedIn YouTube Instagram

To navigate the following site navigation expect to utilize the tab key to move through items sequentially. The spacebar or enter keys can be utilized to interact with items that open sub-navigation.

The next tab will be the search box toggle. Hit enter to open the search, focus will automatically shift to the search bar. Type a letter into the search input and suggested results will appear.

Drug

MTX-463

Status:

Phase 2

Condition:

Idiopathic Pulmonary Fibrosis

Intervention Type:

Intravenous (IV) Injection

Funder Type:

Industry

Drug Details

MTX-463 is a human IgG1 monoclonal antibody that targets and neutralizes WNT1-inducible signaling pathway protein-1 (WISP1), also known as CCN-4. WISP1 is a protein that promotes the growth of myofibroblasts, which are the primary pathogenic cells that drive fibrosis in the lungs.

Study Purpose

This study is a randomized, double-blind, phase 2a, placebo-controlled study on the safety and efficacy of MTX-463 in participants with idiopathic pulmonary fibrosis (IPF).

Find a Clinical Trial